PL215132B1 - Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca - Google Patents

Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca

Info

Publication number
PL215132B1
PL215132B1 PL374920A PL37492003A PL215132B1 PL 215132 B1 PL215132 B1 PL 215132B1 PL 374920 A PL374920 A PL 374920A PL 37492003 A PL37492003 A PL 37492003A PL 215132 B1 PL215132 B1 PL 215132B1
Authority
PL
Poland
Prior art keywords
mmol
general procedure
compound
thiazol
urea
Prior art date
Application number
PL374920A
Other languages
English (en)
Polish (pl)
Other versions
PL374920A1 (en
Inventor
Dharma Rao Polisetti
János Tibor Kodra
Jesper Lau
Paw Bloch
Maria Carmen Valcarce-Lopez
Niels Blume
Mustafa Guzel
Kalpathy Chidambareswaran Santhosh
Adnan M. M. Mjalli
Robert Carl Andrews
Govindan Subramanian
Michael Ankersen
Per Vedsø
Anthony Murray
Lone Jeppesen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL374920A1 publication Critical patent/PL374920A1/xx
Publication of PL215132B1 publication Critical patent/PL215132B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
PL374920A 2002-06-27 2003-06-27 Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca PL215132B1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200200999 2002-06-27
US39414402P 2002-07-03 2002-07-03
DKPA200300286 2003-02-25
US45222803P 2003-03-05 2003-03-05

Publications (2)

Publication Number Publication Date
PL374920A1 PL374920A1 (en) 2005-11-14
PL215132B1 true PL215132B1 (pl) 2013-10-31

Family

ID=30003872

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374920A PL215132B1 (pl) 2002-06-27 2003-06-27 Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca

Country Status (12)

Country Link
US (5) US7384967B2 (US08063081-20111122-C00069.png)
EP (2) EP2471533A1 (US08063081-20111122-C00069.png)
JP (3) JP4881559B2 (US08063081-20111122-C00069.png)
KR (1) KR101116627B1 (US08063081-20111122-C00069.png)
AU (1) AU2003243921B2 (US08063081-20111122-C00069.png)
BR (1) BR0312023A (US08063081-20111122-C00069.png)
CA (2) CA2744893A1 (US08063081-20111122-C00069.png)
IL (1) IL165532A (US08063081-20111122-C00069.png)
MX (1) MXPA05000130A (US08063081-20111122-C00069.png)
NO (1) NO20111028L (US08063081-20111122-C00069.png)
PL (1) PL215132B1 (US08063081-20111122-C00069.png)
WO (1) WO2004002481A1 (US08063081-20111122-C00069.png)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CZ2004747A3 (cs) * 2001-12-21 2004-11-10 Novo Nordisk A/S Deriváty amidů jako GK aktivátory
ES2416304T3 (es) 2002-01-18 2013-07-31 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
JP4881559B2 (ja) * 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
CA2501063A1 (en) * 2002-10-03 2004-04-15 Ecole Polytechnique Federale De Lausanne (Epfl) Substrates for o6-alkylguanine-dna alkyltransferase
CA2498089A1 (en) 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
CA2519265A1 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
WO2005005389A2 (en) * 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
BRPI0415179A (pt) 2003-10-07 2006-11-28 Renovis Inc derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
CA2543054C (en) * 2003-10-23 2013-02-12 Bayer Cropscience Ag Isopentylcarboxanilides for combating undesired micro-organisms
DE10352067A1 (de) * 2003-10-23 2005-05-25 Bayer Cropscience Ag Isopentylcarboxanilide
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
DK1723128T3 (da) * 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
RU2392275C2 (ru) 2004-02-18 2010-06-20 Астразенека Аб Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
CA2561157A1 (en) 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
CA2560689C (en) 2004-04-02 2011-03-01 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2005113511A1 (en) * 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
CA2858901C (en) 2004-06-04 2024-01-16 Carolyn Anderson Diabetes care host-client architecture and data management system
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US20080026987A1 (en) * 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
RU2410384C2 (ru) 2004-06-17 2011-01-27 Цитокинетикс, Инк. Соединения, композиции и способы их использования
SG156650A1 (en) 2004-07-16 2009-11-26 Sunesis Pharmaceuticals Inc Thienopyrimidines useful as aurora kinase inhibitors
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7410988B2 (en) 2004-08-13 2008-08-12 Genentech, Inc. 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7332529B2 (en) * 2004-10-26 2008-02-19 Carr Andrew J Thermoreversible organogelators, compositions and methods of making thereof
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
JP2008521864A (ja) 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッド ヘテロ芳香族グルコキナーゼ活性化剤
WO2006062982A2 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) * 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2006078621A2 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
KR20080027890A (ko) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
CA2614518A1 (en) 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
ES2382815T3 (es) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
AU2006268406C1 (en) 2005-07-09 2011-02-24 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
CA2615938C (en) 2005-07-14 2014-04-29 Novo-Nordisk A/S Urea glucokinase activators
DE102005033103A1 (de) * 2005-07-15 2007-01-25 Bayer Healthcare Ag Heterocyclylamid-substituierte Thiazole, Pyrrole und Thiophene
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1931337B1 (en) 2005-09-29 2013-10-23 Sanofi Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
US20070185098A1 (en) * 2006-01-04 2007-08-09 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
CA2647391C (en) 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
CA2660283C (en) * 2006-08-08 2014-11-18 Akarx, Inc. 2-acylaminothiazole compositions and methods for increasing blood platlelet levels in humans
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
EP2099777B1 (en) * 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
US8940900B2 (en) 2007-02-28 2015-01-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
NZ584049A (en) * 2007-09-21 2011-05-27 Sanofi Aventis (carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
EP2294053B1 (en) 2008-05-16 2016-01-06 Takeda California, Inc. Glucokinase activators
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2358720B1 (en) 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
JP2013501811A (ja) * 2009-08-14 2013-01-17 エーザイ インコーポレーテッド 血小板産生を刺激するためのｅ５５０１の使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011095997A1 (en) 2010-02-08 2011-08-11 Advinus Therapeutics Private Limited Benzamide compounds as glucokinase activators and their pharmaceutical application
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
CN102906077B (zh) 2010-05-26 2015-03-04 转化技术制药有限责任公司 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
US20130197229A1 (en) 2010-10-13 2013-08-01 Christopher Matthews Method of making azaindazole derivatives
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
PL2763984T3 (pl) 2011-10-03 2016-10-31 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
TWI519515B (zh) 2011-12-21 2016-02-01 諾維拉治療公司 Ｂ型肝炎抗病毒劑
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112014028622A2 (pt) 2012-05-17 2017-06-27 Transtech Pharma Llc composições de ativador de glucoquinase para o tratamento de diabetes
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EA027280B1 (ru) 2012-08-28 2017-07-31 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
CN104662013A (zh) 2012-09-26 2015-05-27 兴和株式会社 新型的苯基乙酰胺化合物及含有其的药物
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
WO2014062511A1 (en) * 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CN105143222B (zh) 2013-03-14 2018-02-02 默克专利有限公司 糖苷酶抑制剂
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6449845B2 (ja) 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
BR112015028538A2 (pt) 2013-05-17 2017-07-25 Janssen Sciences Ireland Uc derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (US08063081-20111122-C00069.png) 2013-07-25 2018-07-21
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
DK3054936T5 (da) 2013-10-10 2024-03-18 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (ru) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Комбинированная терапия для лечения инфекций вгв
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
DK3105222T3 (en) 2014-02-14 2018-07-23 Respivert Ltd AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY COMPOUNDS
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
BR112018011389A2 (pt) 2015-12-11 2018-12-04 Teijin Pharma Limited ?composto, composição farmacêutica, regulador de atividade para um receptor de androgênio, e, agente preventivo ou terapêutico?
EA201891438A1 (ru) 2016-02-25 2019-01-31 Асенейрон С. А. Кислотно-аддитивные соли производных пиперазина
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CN108884078A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
US10246453B2 (en) 2016-05-20 2019-04-02 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
CA3042004A1 (en) 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
ES2950757T3 (es) 2017-10-06 2023-10-13 Forma Therapeutics Inc Inhibición de la peptidasa específica de la ubiquitina 30
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
TW202012414A (zh) 2018-04-12 2020-04-01 美商拓臻股份有限公司 三環ask1抑制劑
CA3142097A1 (en) * 2018-05-30 2019-12-05 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
WO2019241089A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
LT3837256T (lt) 2018-08-17 2023-06-12 Novartis Ag Karbamido junginiai ir kompozicijos kaip smarca2 / brm atfazės inhibitoriai
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
AU2019331005B2 (en) 2018-08-31 2024-03-28 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
CA3104913A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
SG11202102815SA (en) 2018-10-05 2021-04-29 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN117881656A (zh) * 2021-08-25 2024-04-12 巴斯夫欧洲公司 除草剂丙二酰胺
WO2023044364A1 (en) 2021-09-15 2023-03-23 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7428A (US08063081-20111122-C00069.png)
US2431801A (en) * 1944-01-11 1947-12-02 George A Gibson Pressure compensated thermostat
GB771147A (en) 1954-06-04 1957-03-27 Merck & Co Inc Derivatives of urea
US3152136A (en) 1958-10-30 1964-10-06 Dow Chemical Co Dinitroaroyl-nu-pyridyl amides
US3067250A (en) * 1959-01-26 1962-12-04 Dow Chemical Co 4-aryl, 1, 1-di propynyl-semicarbazides
US3317534A (en) * 1963-10-30 1967-05-02 Chugai Pharmaceutical Co Ltd Benzamidopyrimidines
US3551442A (en) * 1965-04-06 1970-12-29 Pechiney Saint Gobain Thiazole derivatives
ZA6706928B (US08063081-20111122-C00069.png) 1967-03-23
CH493195A (de) 1968-01-23 1970-07-15 Ciba Geigy Schädlingsbekämpfungsmittel
US4175081A (en) * 1968-02-01 1979-11-20 Mobil Oil Corporation 5-Substituted thiadiazole ureas
GB1195672A (en) 1968-02-01 1970-06-17 Mobil Oil Corp Novel Urea Derivatives and Herbicides containing the same
FR7428M (US08063081-20111122-C00069.png) 1968-05-06 1969-11-12
CH498859A (de) 1968-07-17 1970-11-15 Agripat Sa Verfahren zur Herstellung von Thiadiazolyl-harnstoffen
BE754783A (fr) 1969-08-15 1971-02-12 May & Baker Ltd Derives thiazolyl a usage herbicide leur preparation et les compositions qui les contiennent
GB1266769A (US08063081-20111122-C00069.png) 1969-08-15 1972-03-15
GB1318291A (en) * 1970-04-15 1973-05-23 Shell Int Research Carboxamide derivatives and fungicidal compositions containing them
AT297799B (de) 1970-06-15 1972-04-10 Reichert Optische Werke Ag Temperaturkompensierte Transistor-Gleichspannungs-Vorverstärkerstufe
NL7106557A (US08063081-20111122-C00069.png) 1970-06-15 1971-12-17
IT960595B (it) 1971-06-16 1973-11-30 Hispaco Ag Navetta per tessitura
US3887709A (en) 1971-09-16 1975-06-03 Zdzislaw Brzozowski 2-Pyrazoline-1-carboxamide sulfonamide derivatives useful as hypoglycemic agents
US3862163A (en) * 1971-10-14 1975-01-21 Schering Ag Phenoxycarboxylic acid amides
DE2151766C3 (de) 1971-10-14 1981-03-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-Thiazolinyl-phenoxycarbonsäureamide
US3874873A (en) * 1972-03-27 1975-04-01 Fmc Corp Herbicidal compositions based on 1,2,3-thiadiazol-5-yl ureas
IE38778B1 (en) 1973-02-02 1978-05-24 Ciba Geigy New 1,2,4-benzotriazine derivatives
JPS5614643B2 (US08063081-20111122-C00069.png) 1973-07-02 1981-04-06
AR206720A1 (es) 1974-08-30 1976-08-13 Lilly Co Eli Procedimiento para la preparacion de novedosas n-2-(6-hidroxibenzotiazolil)-n'-fenil(o fenilo substituido)-ureas
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
PL106114B1 (pl) * 1976-12-31 1979-11-30 Akad Medyczna Sposob wytwarzania nowych n-(4-/2-/pirazolo-1-karbonamido/-etylo/-benzenosulfonylo)-mocznikow
DE2712630A1 (de) * 1977-03-23 1978-09-28 Bayer Ag 1,3,4-thiadiazol-2-yl-harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
DE2716324A1 (de) 1977-04-07 1978-10-12 Schering Ag 1,2,3-thiadiazol-3-in-5-yliden- harnstoffe, verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit wachstumsregulatorischer wirkung fuer pflanzen
JPS6033109B2 (ja) * 1977-04-28 1985-08-01 塩野義製薬株式会社 尿素誘導体の合成法
US4241072A (en) 1979-01-18 1980-12-23 Merck & Co., Inc. Substituted ureas and processes for their preparation
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IL72093A0 (en) 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives
US4694004A (en) 1984-07-09 1987-09-15 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US4808722A (en) 1985-10-31 1989-02-28 Fmc Corporation Pyridinylurea N-oxide compounds and agricultural uses
JPS6456660A (en) 1987-05-11 1989-03-03 Sumitomo Chemical Co Urea derivative or its salt, production thereof and germicide for agriculture and horticulture containing said derivative or salt thereof as active ingredient
JPH0453257Y2 (US08063081-20111122-C00069.png) 1987-09-30 1992-12-15
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
RU2021258C1 (ru) 1991-02-28 1994-10-15 Агролинц Агрархемикалиен ГмбХ Способ получения несимметрично дизамещенных мочевин
US5371086A (en) * 1991-03-15 1994-12-06 The Green Cross Corporation Aminopyridine compounds
JPH05294935A (ja) * 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
JPH04334374A (ja) * 1991-05-07 1992-11-20 Mitsui Toatsu Chem Inc Ｎ−（２−チアゾリル）尿素誘導体、その製造方法および該化合物を含有する殺虫剤
EP0642498A1 (en) * 1992-05-28 1995-03-15 Pfizer Inc. NEW $i(N)-ARYL AND $i(N)-HETEROARYLUREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A:CHOLESTEROL ACYL TRANSFERASE (ACAT)
JP3176137B2 (ja) 1992-07-02 2001-06-11 大正製薬株式会社 ビウレット誘導体
JPH06102611A (ja) * 1992-09-22 1994-04-15 Konica Corp ハロゲン化銀写真感光材料
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
US5849769A (en) * 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
US5556969A (en) * 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US6579314B1 (en) 1995-03-10 2003-06-17 C.R. Bard, Inc. Covered stent with encapsulated ends
AU6112896A (en) * 1995-06-07 1996-12-30 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE69626660T2 (de) 1995-09-08 2003-08-21 Novo Nordisk As 2-alkylpyrrolidine
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
KR19990077319A (ko) 1996-01-17 1999-10-25 한센 핀 베네드, 안네 제헤르 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
EP0885890A1 (en) 1996-02-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
JP4339402B2 (ja) 1996-12-31 2009-10-07 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用
US5846985A (en) * 1997-03-05 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JP2001518069A (ja) 1997-05-02 2001-10-09 ドクター・レディーズ・リサーチ・ファウンデーション 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999003861A1 (en) 1997-07-16 1999-01-28 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6268384B1 (en) * 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
TW415942B (en) * 1997-09-03 2000-12-21 American Home Prod Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
HUP0102101A3 (en) * 1997-11-10 2002-11-28 Bristol Myers Squibb Co Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU755654C (en) 1997-11-14 2007-03-29 Kowa Company Ltd. Novel amide compounds and drugs containing the same
JP4391597B2 (ja) 1997-12-02 2009-12-24 ドクター・レディーズ・ラボラトリーズ・リミテッド 抗糖尿病性、低脂質性及び抗高血圧性を有するチアゾリンジオンとオキサゾリジンジオン誘導体
MXPA00006233A (es) * 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
NZ505844A (en) * 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
AU2108099A (en) 1998-01-30 1999-08-16 Procept, Inc. Immunosuppressive agents
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
EP1123268A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU6325799A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
US6353018B1 (en) 1998-10-21 2002-03-05 Novo Nordisk A/S Compounds, their preparation and use
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
CN1332726A (zh) 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
PL348237A1 (en) 1998-12-18 2002-05-20 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2000042023A1 (en) 1999-01-18 2000-07-20 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002539119A (ja) 1999-03-08 2002-11-19 バイエル アクチェンゲゼルシャフト チアゾリルウレア誘導体および抗ウイルス剤としてのそれらの使用
MXPA01009814A (es) * 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
AU3957800A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
CA2370401A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
EP1171414A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
JP2002542237A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
AR035011A1 (es) * 1999-06-30 2004-04-14 Daiichi Seiyaku Co Compuestos inhibidores de vla-4
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
CN1238343C (zh) * 1999-09-09 2006-01-25 组合化学工业株式会社 嘧啶衍生物及含有该衍生物的除草剂
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU2001236698A1 (en) * 2000-02-07 2001-08-14 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
US6410533B1 (en) 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
ES2248309T3 (es) 2000-05-03 2006-03-16 F. Hoffmann-La Roche Ag Activadores de glucoquinasa conteniendo hidantoina.
CA2407416C (en) 2000-05-03 2006-07-18 Paige Erin Mahaney Alkynyl phenyl heteroaromatic glucokinase activators
ES2230309T3 (es) 2000-05-08 2005-05-01 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa.
AU6591401A (en) 2000-05-08 2001-11-20 Hoffmann La Roche Para-amine substituted phenylamide glucokinase activators
WO2002000216A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
ES2243547T3 (es) * 2000-07-20 2005-12-01 F. Hoffmann-La Roche Ag Bencenacetamida sustituida para alfa-acilo y alfa heteroatomos como activador de glucokinasa.
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
AU2002223501A1 (en) * 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
KR100545431B1 (ko) * 2000-12-06 2006-01-24 에프. 호프만-라 로슈 아게 축합된 이종방향족 글루코키나제 활성화제
PL365443A1 (en) * 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EP1256578B1 (en) * 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
JP2003021704A (ja) 2001-07-10 2003-01-24 Nippon Sheet Glass Co Ltd 一組の屈折率分布型ロッドレンズ及び該レンズを備えたマイクロ化学システム
US6916814B2 (en) * 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
DE60221627D1 (de) * 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
CZ2004747A3 (cs) * 2001-12-21 2004-11-10 Novo Nordisk A/S Deriváty amidů jako GK aktivátory
JP4881559B2 (ja) * 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
TW200505894A (en) 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
DK1723128T3 (da) * 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
JP4334374B2 (ja) * 2004-03-05 2009-09-30 株式会社東芝 被ばく線量評価方法、被ばく線量評価システムおよび被ばく線量評価プログラム
CA2614518A1 (en) 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
CA2615938C (en) * 2005-07-14 2014-04-29 Novo-Nordisk A/S Urea glucokinase activators
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
EP2099777B1 (en) * 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators

Also Published As

Publication number Publication date
IL165532A (en) 2013-06-27
IL165532A0 (en) 2006-01-15
EP1531815A1 (en) 2005-05-25
AU2003243921B2 (en) 2009-05-07
US20110301158A1 (en) 2011-12-08
AU2003243921A1 (en) 2004-01-19
JP4881559B2 (ja) 2012-02-22
CA2488642C (en) 2011-09-06
BR0312023A (pt) 2005-03-22
US20080119454A1 (en) 2008-05-22
KR101116627B1 (ko) 2012-10-09
WO2004002481A1 (en) 2004-01-08
CA2488642A1 (en) 2004-01-08
PL374920A1 (en) 2005-11-14
MXPA05000130A (es) 2005-02-17
NO20111028L (no) 2005-03-29
USRE45670E1 (en) 2015-09-15
CA2744893A1 (en) 2004-01-08
US7384967B2 (en) 2008-06-10
US7897628B2 (en) 2011-03-01
EP2471533A1 (en) 2012-07-04
KR20050019801A (ko) 2005-03-03
US8063081B2 (en) 2011-11-22
US20040122235A1 (en) 2004-06-24
JP2011168609A (ja) 2011-09-01
JP2005537333A (ja) 2005-12-08
JP2010265306A (ja) 2010-11-25
US20080119455A1 (en) 2008-05-22
EP1531815B1 (en) 2014-09-24

Similar Documents

Publication Publication Date Title
PL215132B1 (pl) Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
KR101124245B1 (ko) 치료제로서 아릴 카르보닐 유도체
KR101018318B1 (ko) Ｇｋ 활성제로서의 아미드 유도체
US8148412B2 (en) Heteroaromatic glucokinase activators
KR101126225B1 (ko) 헤테로아릴-유리아 및 글루코키나아제 활성제로서의 그들의 사용
AU2008225613B2 (en) Glucokinase activator
EP1921074A1 (en) Thiazole derivative
TW200303207A (en) Amide derivatives as therapeutic agents
ES2526192T3 (es) Activadores de la glucocinasa

Legal Events

Date Code Title Description
RECP Rectifications of patent specification